CNBX Pharmaceuticals (CNBX Pharmaceuticals) FCF Margin % : -302.44% (As of Feb. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CNBX Pharmaceuticals's Free Cash Flow for the three months ended in Feb. 2024 was $-0.12 Mil. CNBX Pharmaceuticals's Revenue for the three months ended in Feb. 2024 was $0.04 Mil. Therefore, CNBX Pharmaceuticals's FCF Margin % for the quarter that ended in Feb. 2024 was -302.44%.

As of today, CNBX Pharmaceuticals's current FCF Yield % is -63.73%.

The historical rank and industry rank for CNBX Pharmaceuticals's FCF Margin % or its related term are showing as below:

CNBX' s FCF Margin % Range Over the Past 10 Years
Min: -40728.57 Med: -16500 Max: -27.56
Current: -36.11

During the past 13 years, the highest FCF Margin % of CNBX Pharmaceuticals was -27.56%. The lowest was -40728.57%. And the median was -16500.00%.

CNBX's FCF Margin % is ranked better than
64.56% of 1044 companies
in the Biotechnology industry
Industry Median: -146.375 vs CNBX: -36.11

CNBX Pharmaceuticals FCF Margin % Historical Data

The historical data trend for CNBX Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals FCF Margin % Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

FCF Margin %

Get a 7-Day Free Trial

-33,110.00

-40,728.57

-5,603.33

-27.56

CNBX Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
FCF Margin %	Get a 7-Day Free Trial															-	-6.13	21.00	-82.02	-302.44

Competitive Comparison of CNBX Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, CNBX Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNBX Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's FCF Margin % falls into.

CNBX Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

CNBX Pharmaceuticals's FCF Margin for the fiscal year that ended in Aug. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Aug. 2023 )	/	Revenue (A: Aug. 2023 )
	=	-0.113	/	0.41
	=	-27.56 %

CNBX Pharmaceuticals's FCF Margin for the quarter that ended in Feb. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Feb. 2024 )	/	Revenue (Q: Feb. 2024 )
	=	-0.124	/	0.041
	=	-302.44 %

CNBX Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary